Equillium (EQ)
Market Price (2/4/2026): $1.51 | Market Cap: $98.6 MilSector: Health Care | Industry: Biotechnology
Equillium (EQ)
Market Price (2/4/2026): $1.51Market Cap: $98.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% | Weak multi-year price returns3Y Excs Rtn is -21% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -555% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Stock price has recently run up significantly6M Rtn6 month market price return is 153%, 12M Rtn12 month market price return is 127% | |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -90%, Rev Chg QQuarterly Revenue Change % is null | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 55% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -522%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -522% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 628% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -29% | ||
| High stock price volatilityVol 12M is 172% | ||
| Key risksEQ key risks include [1] significant regulatory uncertainty for its lead drug itolizumab after the FDA declined to support an accelerated approval pathway, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -21% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -555% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 153%, 12M Rtn12 month market price return is 127% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -90%, Rev Chg QQuarterly Revenue Change % is null |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 55% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -522%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -522% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 628% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -29% |
| High stock price volatilityVol 12M is 172% |
| Key risksEQ key risks include [1] significant regulatory uncertainty for its lead drug itolizumab after the FDA declined to support an accelerated approval pathway, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Equillium (EQ) stock has gained about 5% since 10/31/2025 because of the following key factors:
1. Strengthened Financial Position with Extended Runway
Equillium secured significant financing through a private placement of up to $50 million, with an initial tranche of approximately $30 million. This funding, announced in August 2025 and highlighted in the Q3 2025 financial results reported in November 2025, is expected to extend the company's cash runway through 2027, addressing previous concerns about limited cash and providing stability for its development programs.
2. Strategic Focus on EQ504 and Anticipated Clinical Progression
The company sharpened its therapeutic pipeline focus on EQ504, a novel aryl hydrocarbon receptor (AhR) modulator for severe inflammatory diseases. Equillium announced plans to initiate the Phase 1 clinical study for EQ504 in mid-2026, with the potential to achieve proof-of-concept by adding ulcerative colitis patient cohorts, which presented a clear and positive development pathway for its lead candidate.
Show more
1. Strengthened Financial Position with Extended Runway
Equillium secured significant financing through a private placement of up to $50 million, with an initial tranche of approximately $30 million. This funding, announced in August 2025 and highlighted in the Q3 2025 financial results reported in November 2025, is expected to extend the company's cash runway through 2027, addressing previous concerns about limited cash and providing stability for its development programs.
2. Strategic Focus on EQ504 and Anticipated Clinical Progression
The company sharpened its therapeutic pipeline focus on EQ504, a novel aryl hydrocarbon receptor (AhR) modulator for severe inflammatory diseases. Equillium announced plans to initiate the Phase 1 clinical study for EQ504 in mid-2026, with the potential to achieve proof-of-concept by adding ulcerative colitis patient cohorts, which presented a clear and positive development pathway for its lead candidate.
Show more
Stock Movement Drivers
Fundamental Drivers
The 7.1% change in EQ stock from 10/31/2025 to 2/3/2026 was primarily driven by a 638.1% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.41 | 1.51 | 7.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 17 | 4 | -73.5% |
| P/S Multiple | 3.0 | 22.5 | 638.1% |
| Shares Outstanding (Mil) | 36 | 65 | -45.3% |
| Cumulative Contribution | 7.1% |
Market Drivers
10/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| EQ | 7.1% | |
| Market (SPY) | 1.1% | 10.7% |
| Sector (XLV) | 6.8% | -5.8% |
Fundamental Drivers
The 286.2% change in EQ stock from 7/31/2025 to 2/3/2026 was primarily driven by a 4807.6% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.39 | 1.51 | 286.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 30 | 4 | -85.6% |
| P/S Multiple | 0.5 | 22.5 | 4807.6% |
| Shares Outstanding (Mil) | 36 | 65 | -45.5% |
| Cumulative Contribution | 286.2% |
Market Drivers
7/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| EQ | 286.2% | |
| Market (SPY) | 9.4% | -7.9% |
| Sector (XLV) | 18.7% | 1.6% |
Fundamental Drivers
The 135.9% change in EQ stock from 1/31/2025 to 2/3/2026 was primarily driven by a 4448.2% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.64 | 1.51 | 135.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 46 | 4 | -90.4% |
| P/S Multiple | 0.5 | 22.5 | 4448.2% |
| Shares Outstanding (Mil) | 35 | 65 | -45.8% |
| Cumulative Contribution | 135.9% |
Market Drivers
1/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| EQ | 135.9% | |
| Market (SPY) | 15.6% | 3.9% |
| Sector (XLV) | 6.3% | 3.3% |
Fundamental Drivers
The 39.8% change in EQ stock from 1/31/2023 to 2/3/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.08 | 1.51 | 39.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 4 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 22.5 | |
| Shares Outstanding (Mil) | 34 | 65 | -47.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/3/2026| Return | Correlation | |
|---|---|---|
| EQ | 39.8% | |
| Market (SPY) | 75.9% | 10.4% |
| Sector (XLV) | 20.9% | 8.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EQ Return | -30% | -72% | -32% | 3% | 107% | -3% | -72% |
| Peers Return | -16% | -28% | -41% | -66% | -32% | 9% | -91% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| EQ Win Rate | 50% | 33% | 42% | 50% | 42% | 50% | |
| Peers Win Rate | 36% | 50% | 53% | 29% | 56% | 100% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| EQ Max Drawdown | -30% | -78% | -55% | -17% | -61% | -32% | |
| Peers Max Drawdown | -30% | -45% | -60% | -67% | -49% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ACSB, AKTS, ALPS, APRI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/3/2026 (YTD)
How Low Can It Go
| Event | EQ | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -95.5% | -25.4% |
| % Gain to Breakeven | 2104.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -86.9% | -33.9% |
| % Gain to Breakeven | 661.5% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -84.6% | -19.8% |
| % Gain to Breakeven | 548.0% | 24.7% |
| Time to Breakeven | 263 days | 120 days |
Compare to VRTX, ACSB, AKTS, ALPS, APRI
In The Past
Equillium's stock fell -95.5% during the 2022 Inflation Shock from a high on 2/12/2021. A -95.5% loss requires a 2104.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Equillium (EQ)
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
AI Analysis | Feedback
Here are 1-2 brief analogies for Equillium (EQ):
- A clinical-stage biotech developing drugs for autoimmune and inflammatory diseases, akin to an earlier Biogen or Amgen.
- An emerging drug developer focused on autoimmune conditions, similar to an earlier Regeneron.
AI Analysis | Feedback
- Itolizumab (EQ001): A novel first-in-class monoclonal antibody designed to target the CD6-ALCAM pathway for severe autoimmune and inflammatory diseases.
- EQ101: A next-generation product candidate also targeting the CD6-ALCAM pathway, engineered for enhanced potency and pharmacokinetic properties.
- EQ302: An oral, highly selective, small molecule inhibitor of TYK2, being developed for systemic autoimmune and inflammatory diseases.
AI Analysis | Feedback
Equillium (EQ) is a clinical-stage biotechnology company focused on developing novel immunomodulatory drugs. As a clinical-stage company, it does not yet have commercial products on the market and therefore does not sell directly to individuals or commercialize drugs through healthcare providers.
Equillium's revenue primarily comes from collaboration agreements with other pharmaceutical companies for the development and commercialization of its drug candidates.
Based on its latest financial filings (e.g., the 2023 10-K), its major customer and source of all collaboration revenue is:
- Otsuka Pharmaceutical Co., Ltd. (a subsidiary of the public company, Otsuka Holdings Co., Ltd. TYO: 4768)
AI Analysis | Feedback
Biocon Limited (BSE: 532480, NSE: BIOCON)
AI Analysis | Feedback
Bruce Steel, CFA Chief Executive Officer Bruce Steel is a co-founder, Director, and Chief Executive Officer of Equillium. Prior to co-founding Equillium, he was the founder and Managing Director of BioMed Ventures, where he directed investments in over 30 biotechnology companies. He also co-founded and served as CEO of Rincon Pharmaceuticals, which was acquired in 2008. Stephen Connelly, Ph.D. President and Chief Scientific Officer Stephen Connelly is a co-founder, Director, President, and Chief Scientific Officer of Equillium. Before co-founding Equillium, he was an investment Principal at BioMed Ventures, a life sciences venture capital group, and previously served as Director of Business Development and Therapeutic Alliances at aTyr. Christine Zedelmayer, PMP Chief Operating Officer Christine Zedelmayer is the Chief Operating Officer at Equillium. Her prior experience includes serving as Principal Consultant at Centerra Consulting, a project management and investor relations consulting firm for life sciences companies. She has also held leadership positions in project management at Amgen, Ligand Pharmaceuticals, and Hybritech. Penny Tom, CPA Senior Vice President, Finance & Principal Accounting Officer Penny Tom joined Equillium in January 2019 and serves as Senior Vice President, Finance & Principal Accounting Officer. She possesses over 30 years of experience in financial reporting, finance operations, and Sarbanes-Oxley compliance, with a background in both public and private life science companies and Big 4 public accounting. Joel Rothman Chief Development Officer Joel Rothman is the Chief Development Officer at Equillium, bringing over 25 years of experience in advancing therapeutics. He previously led development operations in Vice President roles at companies such as Cytokinetics, Raptor Pharmaceuticals (acquired by Horizon Pharma), and Jazz Pharmaceuticals. His career also includes directing clinical operations, orchestrating due diligence, corporate acquisitions, and integrations.AI Analysis | Feedback
Key Risks to Equillium (EQ):
- Clinical and Regulatory Risk: Equillium's business is highly dependent on the successful development, regulatory approval, and commercialization of its product candidates. The company, a clinical-stage biotechnology firm, recently faced a setback when the U.S. Food and Drug Administration (FDA) declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway for itolizumab in acute graft-versus-host disease (aGVHD) based on Day 29 outcomes from the Phase 3 EQUATOR study. While longer-term outcomes showed statistical significance, the FDA's focus on earlier endpoints introduces regulatory uncertainty. The ongoing and future clinical studies for its pipeline assets, including EQ504 and EQ302, face inherent uncertainties regarding enrollment, regulatory acceptance, and overall results.
- Financial Position and Need for Additional Capital: Equillium has a history of significant operating losses and anticipates incurring substantial net losses for the foreseeable future. While the company recently closed a financing of up to $50 million, with an initial tranche of $30 million expected to provide a cash runway through 2027, its ability to raise additional capital on acceptable terms remains a critical risk. As of March 31, 2025, Equillium's cash and cash equivalents were $14.5 million, which was projected to fund operations only into the third quarter of 2025 based on certain assumptions. The company has explicitly identified its ability to continue as a going concern as a risk, underscoring the ongoing need for substantial additional funding to complete its development programs.
- Competition and Market Acceptance: Equillium operates in a highly competitive biotechnology sector, developing therapeutics for severe autoimmune and inflammatory disorders. Changes in the competitive landscape, including new breakthroughs by other biotech firms, could significantly impact Equillium's market position and stock performance. Furthermore, even if its product candidates successfully navigate clinical trials and receive regulatory approval, there is no guarantee that they will achieve the necessary market acceptance for commercial success, as the company currently lacks a dedicated marketing and sales organization.
AI Analysis | Feedback
The emergence of B-cell targeted CAR-T cell therapies for severe autoimmune diseases represents a clear emerging threat. Companies like Kyverna Therapeutics (acquired by Vertex Pharmaceuticals) and Cabaletta Bio are advancing clinical trials for conditions such as lupus nephritis and systemic lupus erythematosus, which are key indications for Equillium's lead product candidate, itolizumab. While still in early clinical stages, these CAR-T therapies represent a potentially disruptive modality. They aim to achieve profound, long-lasting remission by directly eliminating pathogenic B-cells, a mechanism distinct from and potentially more impactful than Equillium's CD6-targeted immune modulation. If successful, these highly potent therapies could offer superior efficacy and durability for severe, refractory autoimmune patients, potentially capturing a significant portion of the market currently addressed by or targeted by traditional biologic therapies.
AI Analysis | Feedback
```htmlEquillium (EQ) is a clinical-stage biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders. Their main product candidates and their addressable markets are as follows:
- Itolizumab (EQ001) for Lupus Nephritis: The global lupus nephritis market size was valued at approximately USD 2.31 billion in 2024. This market is projected to reach about USD 8.50 billion by 2025, with a Compound Annual Growth Rate (CAGR) of around 12.5% from 2025 to 2033. In 2024, North America held a significant market share, valued at USD 925.80 million, and is expected to grow at a CAGR of 7.00% from 2024 to 2031. Another report estimates the market across the top 7 markets (US, EU4, UK, and Japan) at USD 2.4 billion in 2024, expected to reach USD 6.0 billion by 2035 with a CAGR of 8.7%.
- Itolizumab (EQ001) or EQ504 for Ulcerative Colitis: The global ulcerative colitis market size was valued at USD 8 billion in 2024 and is projected to grow at a CAGR of 5.6% from 2025 to 2034. Another estimate for the global ulcerative colitis therapeutics market size indicates a value of USD 9.57 billion in 2024, anticipated to grow to USD 20.06 billion by 2033, with a CAGR of 8.57% during the forecast period (2025–2033). North America's ulcerative colitis market accounted for USD 3.2976 billion in 2022.
- EQ302 for Celiac Disease: The global celiac disease market size was valued at USD 0.71 billion in 2024 and is anticipated to reach USD 1.15 billion by 2029, growing at a CAGR of 10.1%. North America was identified as the largest region in the celiac disease market in 2024.
AI Analysis | Feedback
Equillium (EQ) Expected Drivers of Future Revenue Growth
Over the next 2-3 years, Equillium's revenue growth is anticipated to be driven by several key factors, primarily centered around the advancement and potential commercialization of its lead drug candidates.- Potential Approval and Commercialization of Itolizumab in Acute Graft-Versus-Host Disease (aGVHD): The most significant near-term driver is the potential accelerated approval and subsequent launch of itolizumab for the treatment of acute graft-versus-host disease (aGVHD). Equillium has prioritized itolizumab, and positive topline data from the Phase 3 EQUATOR study in aGVHD, expected in Q1 2025, could pave the way for regulatory feedback and potential accelerated approval from the FDA. Successful commercialization in this indication would represent a critical new revenue stream for the company, which historically has seen revenue primarily from development funding and upfront payments from partnerships.
- Advancement and Potential Commercialization of Itolizumab in Ulcerative Colitis (UC): Another crucial driver is the progress of itolizumab in treating moderate to severe ulcerative colitis. Positive topline data from the Phase 2 study in ulcerative colitis was also expected in Q1 2025. Should these results be favorable and lead to further clinical development and eventual market approval, itolizumab could capture a share in the substantial ulcerative colitis market, diversifying and significantly increasing Equillium's revenue base.
- Clinical Development and Pipeline Progression of EQ504: The company is sharpening its therapeutic pipeline focus on advancing EQ504, a novel aryl hydrocarbon receptor (AhR) modulator, into clinical trials for severe inflammatory diseases, including ulcerative colitis and inflammatory lung diseases. While EQ504 is in earlier stages compared to itolizumab, its progression through clinical development and potential for targeted, local delivery could unlock future revenue opportunities within the 2-3 year timeframe, particularly if early clinical milestones are met and strategic partnerships are formed.
AI Analysis | Feedback
Share Repurchases
- On August 2, 2023, Equillium's Board of Directors authorized a share repurchase program for up to $7.5 million of common stock.
- As of December 31, 2023, the company had repurchased $0.3 million of its common stock under this program.
- This share repurchase program was authorized through the end of 2024 and expired on December 31, 2024, with no further repurchases made after December 31, 2023.
Share Issuance
- In August 2025, Equillium secured up to $50 million in private placement financing, including an initial $30 million upfront in exchange for approximately 52.6 million shares of common stock (or pre-funded warrants) at $0.57 per share.
- In 2021, Equillium issued $31 million in net common equity, which included $29.9 million from a registered direct offering and $1.2 million from employee stock purchase plan and stock option exercises.
- The company reported $54 million in net common equity issued in 2020.
Inbound Investments
- On December 5, 2022, Equillium received a one-time upfront payment of JPY 3.5 billion (approximately $26.4 million) from Ono Pharmaceutical for an option to acquire rights to itolizumab (EQ001).
- Equillium is eligible to receive up to an additional $101.4 million in development and commercialization milestone payments from the Ono Pharmaceutical collaboration.
- In August 2025, Equillium received an initial $30 million from a private placement, with the potential for an additional $20 million upon achieving specific clinical study initiation and share price milestones.
Outbound Investments
- In 2022, Equillium acquired Bioniz Therapeutics, which resulted in $23.0 million in acquired in-process research and development expenses, comprising $22.5 million in non-cash equity consideration and $0.5 million for net liabilities acquired.
Capital Expenditures
- Capital expenditures for property and equipment were $0.1 million in 2023 and $0.3 million in 2022.
- In 2024, capital expenditures for property, plant, and equipment were approximately $90,000.
- Equillium's capital expenditures are primarily focused on maintaining existing facilities and acquiring necessary research and development equipment.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Equillium Earnings Notes | 12/16/2025 | |
| Would You Still Hold Equillium Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 11.21 |
| Mkt Cap | 59.6 |
| Rev LTM | 5,864 |
| Op Inc LTM | -58 |
| FCF LTM | 1,657 |
| FCF 3Y Avg | 1,026 |
| CFO LTM | 1,848 |
| CFO 3Y Avg | 1,204 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -40.1% |
| Rev Chg 3Y Avg | 10.5% |
| Rev Chg Q | -44.5% |
| QoQ Delta Rev Chg LTM | -35.4% |
| Op Mgn LTM | -277.8% |
| Op Mgn 3Y Avg | -85.5% |
| QoQ Delta Op Mgn LTM | -215.1% |
| CFO/Rev LTM | -245.0% |
| CFO/Rev 3Y Avg | -78.6% |
| FCF/Rev LTM | -246.7% |
| FCF/Rev 3Y Avg | -80.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 59.6 |
| P/S | 16.3 |
| P/EBIT | 11.3 |
| P/E | 14.2 |
| P/CFO | 13.9 |
| Total Yield | -10.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -8.7% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 3.0% |
| 3M Rtn | 4.9% |
| 6M Rtn | 88.8% |
| 12M Rtn | 64.3% |
| 3Y Rtn | 42.4% |
| 1M Excs Rtn | 2.1% |
| 3M Excs Rtn | 6.0% |
| 6M Excs Rtn | 75.5% |
| 12M Excs Rtn | 54.2% |
| 3Y Excs Rtn | -23.1% |
Price Behavior
Price Behavior
| Market Price | $1.51 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 10/12/2018 | |
| Distance from 52W High | -24.1% | |
| 50 Days | 200 Days | |
| DMA Price | $1.20 | $0.97 |
| DMA Trend | up | up |
| Distance from DMA | 26.3% | 56.5% |
| 3M | 1YR | |
| Volatility | 137.7% | 172.2% |
| Downside Capture | 71.16 | 55.05 |
| Upside Capture | 89.81 | 130.65 |
| Correlation (SPY) | 10.5% | 3.9% |
EQ Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.66 | 2.82 | 1.24 | 0.67 | 0.34 | 0.90 |
| Up Beta | -6.04 | -2.55 | -3.94 | -2.12 | -0.15 | 0.33 |
| Down Beta | -0.25 | 1.52 | 3.93 | 4.37 | 0.69 | 1.50 |
| Up Capture | -223% | 898% | 112% | 119% | 142% | 101% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 11 | 21 | 28 | 52 | 108 | 352 |
| Down Capture | -106% | 176% | 115% | -118% | 63% | 103% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 8 | 18 | 30 | 68 | 136 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EQ | |
|---|---|---|---|---|
| EQ | 136.4% | 172.3% | 1.20 | - |
| Sector ETF (XLV) | 6.3% | 17.2% | 0.20 | 3.3% |
| Equity (SPY) | 15.6% | 19.2% | 0.63 | 3.8% |
| Gold (GLD) | 77.2% | 24.5% | 2.30 | -5.8% |
| Commodities (DBC) | 10.0% | 16.5% | 0.40 | -6.6% |
| Real Estate (VNQ) | 2.9% | 16.5% | -0.00 | -0.7% |
| Bitcoin (BTCUSD) | -23.4% | 40.3% | -0.56 | 4.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EQ | |
|---|---|---|---|---|
| EQ | -23.9% | 113.9% | 0.25 | - |
| Sector ETF (XLV) | 7.8% | 14.4% | 0.36 | 8.1% |
| Equity (SPY) | 14.5% | 17.0% | 0.68 | 11.4% |
| Gold (GLD) | 21.5% | 16.8% | 1.04 | 1.0% |
| Commodities (DBC) | 12.0% | 18.9% | 0.51 | 2.6% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 9.7% |
| Bitcoin (BTCUSD) | 20.9% | 57.5% | 0.56 | 7.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EQ | |
|---|---|---|---|---|
| EQ | -20.0% | 294.7% | 0.34 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 5.1% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 3.1% |
| Gold (GLD) | 15.6% | 15.5% | 0.84 | 0.5% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | -0.3% |
| Real Estate (VNQ) | 5.6% | 20.8% | 0.24 | 2.4% |
| Bitcoin (BTCUSD) | 69.9% | 66.5% | 1.09 | 2.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | 23.8% | 20.2% | 44.0% |
| 8/4/2025 | -20.7% | -30.3% | 142.3% |
| 3/27/2025 | -35.6% | -35.2% | -42.2% |
| 11/13/2024 | -12.3% | -8.0% | -9.7% |
| 8/8/2024 | -1.5% | 13.9% | 25.8% |
| 5/9/2024 | -15.0% | -14.4% | -60.7% |
| 2/23/2024 | 9.4% | -1.6% | -3.9% |
| 11/8/2023 | -4.7% | 0.0% | 36.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 8 | 7 |
| # Negative | 12 | 11 | 12 |
| Median Positive | 9.4% | 8.7% | 36.0% |
| Median Negative | -6.8% | -13.0% | -17.4% |
| Max Positive | 44.8% | 28.4% | 142.3% |
| Max Negative | -35.6% | -35.2% | -60.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/23/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zedelmayer, Christine | Sr. Vice President and COO | Direct | Sell | 12232025 | 1.50 | 100,000 | 150,000 | 137,166 | Form |
| 2 | Zedelmayer, Christine | Sr. Vice President and COO | Direct | Sell | 12152025 | 1.34 | 23,804 | 31,897 | 138,481 | Form |
| 3 | Zedelmayer, Christine | Sr. Vice President and COO | Direct | Sell | 12152025 | 1.31 | 11,900 | 15,589 | 119,792 | Form |
| 4 | Zedelmayer, Christine | Sr. Vice President and COO | Direct | Sell | 11252025 | 0.95 | 8,098 | 7,696 | 120,838 | Form |
| 5 | Keyes, Jason A | Chief Financial Officer | The Keyes Trust Dated September 10, 2004 | Sell | 1242025 | 0.65 | 10,000 | 6,500 | 24,518 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.